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LPS-matured CD11cþ bone
marrow-derived dendritic cells can
initiate autoimmune pathology with
minimal injection site inflammation
Louise Saul1, Dario Besusso1 and Richard J Mellanby1,2
Abstract
The pathogenesis of human autoimmune disorders is incompletely understood. This has led to the develop-
ment of numerous murine models in which the pathogenesis of autoimmunity can be probed and the efficacy
of novel therapies can be tested. One of the most widely-used murine models of autoimmunity is experimental
autoimmune encephalomyelitis (EAE). To induce autoimmune pathology, mice are often immunized with an
autoantigen alongside an adjuvant, typically complete Freund’s adjuvant (CFA). Unfortunately, CFA causes
significant inflammation at the site of administration. Despite the well-recognized complication of injection
site inflammation, CFA with autoantigen immunization is widely used to induce central nervous system
autoimmunity. We performed a literature review which allowed us to estimate that over 10,000 mice were
immunized with CFA in published EAE studies in 2013. In this study, we demonstrated that subcutaneously
administered myelin basic protein (MBP)-pulsed CD11cþ bone marrow-derived dendritic cells (BMDC) were
as effective at inducing EAE as subcutaneously administered MBP plus CFA. Importantly, we also discovered
that the CD11cþ BMDC caused significantly less injection site inflammation than MBP plus CFA immuniza-
tion. This study demonstrated that the use of CD11cþ BMDC can enable the development of autopathogenic
T-cells to be studied in vivo without the unwanted side-effects of long-lasting injection site inflammation. This
model represents a significant refinement to existing EAE models and may lead to the improvement of the
welfare of experimental mice used to study the development of autoimmunity in vivo.
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Autoimmune diseases, including multiple sclerosis
(MS) and type I diabetes (TID), are a signiﬁcant
cause of morbidity and mortality. There are an esti-
mated 540,000 individuals with MS in Europe and
one million individuals with TID in USA. Collectively
these diseases impose signiﬁcant pain and disability on
patients, shorten life expectancy, and are associated
with huge direct and indirect healthcare costs.1–3
Autoimmune diseases present with tissue lesions sug-
gestive of an immunopathological process, the risk
genes for developing autoimmune diseases are mostly
involved in modulating immune and inﬂammatory
responses, and the most eﬀective treatments of these
diseases modulate the immune response.4
To further understanding of the biology of auto-
immune diseases, a wide range of experimental
murine models have been developed.5,6 One of the ear-
liest and most widely-used autoimmune disease models
is experimental autoimmune encephalomyelitis (EAE).7
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Over 60 years ago, it was demonstrated that adminis-
tration of complete Freund’s adjuvant (CFA) and
central nervous system (CNS) tissue could induce
inﬂammatory lesions, which are similar to human
demyelinating lesions as is typically observed in
patients with MS.7,8 Subsequently, EAE models have
played a major role in advancing understanding of
immune-mediated injury and have been instrumental
in the development of novel MS therapies.7
The diversity of EAE models has greatly expanded
since the model was ﬁrst described.4,7 The injection of
CNS autoantigen responsive T-cells which have acti-
vated ex vivo is also a widely-used technique for indu-
cing EAE.9,10 Spontaneous EAE models have recently
been developed; and ‘humanized mice’, where genes or
cells from human MS patients are transferred into
murine hosts, have also been described.4,6 Despite
these developments, the use of CFA and autoantigens
remains a widely-used approach for inducing auto-
immunity.7 One of the main advantages of the use
of CFA and autoantigens for inducing autoimmunity
is that this allows the development of an autopatho-
genic immune response to be studied in vivo, in con-
trast to passive transfer models which rely on the
administration of ex vivo activated immune cells.
However, one of the major disadvantages of using
CFA in autoimmune models is that it causes long-last-
ing inﬂammation at the site of injection.11 Intradermal
injections of CFA are associated with large palpable
granulomas that often ulcerate,12,13 whereas subcuta-
neous injections can cause exudative, diﬀuse inﬂamma-
tion and ﬁbrosis.12,13 In addition, mice immunized
with CFA show a range of altered behaviours, includ-
ing reduced open ﬁeld activity and reductions in their
distance travelled during forced gait analysis and vol-
untary wheel running.14 Consequently, a recent review
entitled ‘Reducing suﬀering in EAE’ highlighted the
need for careful consideration during adjuvant selec-
tion while taking into account animal welfare
considerations.15
The disadvantages of using an adjuvant alongside
autoantigens to prime naı¨ve T-cells in vivo may poten-
tially be overcome by administering autoantigens
loaded in specialized antigen presenting cells, typically
activated dendritic cells (DC).16 These cells express high
levels of major histocompatibility complex (MHC)
class II molecules and other co-stimulatory molecules
and have the ability to induce proliferation and eﬀector
cytokine production from T-cells that can engage with
their MHC class II and peptide molecules. However, it
has proved diﬃcult to optimize DC-driven EAE
models, and only a small number of studies have
reported the use of DC to initiate EAE in murine
hosts.17–19 We have recently addressed these shortcom-
ings by developing a novel DC-driven EAE model in
which host mice, seeded with myelin basic protein
(MBP) reactive T-cell receptor (TCR) transgenic
CD4þ T-cells, develop a monophasic ascending paraly-
sis following the subcutaneous administration of lipo-
polysaccharide (LPS)-activated, MBP-loaded bone
marrow-derived DC (BMDC).20
Although we have demonstrated that MBP-loaded
BMDC are capable of inducing EAE, it remains
unclear whether our novel model avoids the complica-
tions of subcutaneously administered CFA.
Consequently, the aim of this study was to address
two hypotheses. The ﬁrst hypothesis was that MBP-
loaded BMDC and MBP plus CFA immunizations
were equally eﬀective at inducing EAE. The second
hypothesis was that MBP-loaded DC would cause less
injection site inﬂammation than CFA plus MBP
immunization.
Materials and methods
Literature search for an annual estimate
of mice immunized with CFA in EAE
experiments
A PubMed search of ‘experimental autoimmune
encephalomyelitis AND mice’ between 1 January
2013 and 31 December 2013 was undertaken on
27 October 2014. All abstracts were reviewed to inves-
tigate whether the study used CFA and a CNS auto-
antigen to induce EAE. If this information was not
available in the abstract, the full paper was reviewed.
In order to calculate the average number of mice used
in each study, the ﬁrst 30 papers published in that year
were reviewed in full and the numbers of mice admin-
istered CFA were recorded.
Mice, antigens and tissue culture medium
B10.PLxC56BL/6 (both CD45.2) and Tg4 CD45.1 mice
were bred under speciﬁc pathogen-free conditions at the
University of Edinburgh. All mice used in the experi-
ments reported were female, as this allowed for stand-
ardization of experiment groups and permitted the
housing of mice from diﬀerent litters in the same experi-
mental cage. The mice were maintained in individually-
ventilated cages. The housing facility was compliant
with the Federation of European Laboratory Animal
Science Associations guidelines on screening mice for
infectious diseases. Seventy-one B10.PLxC57BL/6 mice
and eight Tg4 CD45.1 mice aged between six and
10 weeks were used in the experiments. All the experi-
ments had local ethical approval from the University of
Edinburgh’s Animal Welfare and Ethical Review Body
and were performed in accordance with UK legislation.
Tg4 mice express a transgenic TCR recognizing the
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Ac1-9 peptide of MBP in association with I-Au.21
B10.PLxC57BL/6 mice were used as the recipient
mice since immunization with CFA plus MBP or
MBP-loaded BMDC does not result in disease unless
the mice are pre-seeded with MBP responsive Tg4
CD45.1 CD4þ T-cells.22 Consequently this system pro-
vides a highly reﬁned approach which allows the key
autopathogenic T-cells to be tracked in vivo. The MBP
Ac1-9(4Tyr) and Ac1-9(4Lys) peptides were obtained
from Cambridge Research Biochemicals (Cleveland,
UK). Tissue culture medium (RPMI 1640 medium) was
supplemented with 2mM L-glutamine, 100 U/mL peni-
cillin, 100mg/mL streptomycin, and 5 105M 2-ME
(all from Invitrogen Life Technologies, Paisley, UK)
and 10% fetal calf serum (FCS; Sigma–Aldrich,
Dorset, UK).
Active induction of EAE
Female B10.PLxC57BL/6 (CD45.2) mice received
1 106 CD4þ T-cells intravenously which had been
isolated from the spleens of Tg4 CD45.1þ mice using
microbeads as per manufacturer’s instructions
(Miltenyi Biotech, Surrey, UK). One day later (day 0),
mice received 10 mg of the Ac1-9(4Tyr) peptide emulsi-
ﬁed in CFA containing 50 mg of heat-killed
Mycobacterium tuberculosis H37Ra (Sigma–Aldrich)
at a total ﬁnal volume of 100 mL, of which 50 mL
was injected subcutaneously into each hind leg. On
the day of immunization and 48 h later, each mouse
also received 200 ng of pertussis toxin (Health
Protection Agency, Dorset, UK) in 0.5mL phosphate-
buﬀered saline (PBS) intraperitoneally. Clinical signs
of EAE were assessed daily with the following
scoring system: 0, no signs; 1, ﬂaccid tail; 2,
impaired righting reﬂex and/or gait; 3, partial hind
limb paralysis; 4, total hind limb paralysis; 5, hind
limb paralysis with partial front limb paralysis; 6, mori-
bund or dead.
BMDC-driven EAE
BMDC were generated in the presence of recombinant
granulocyte macrophage colony stimulating factor
(GM–CSF; PeproTech, London, UK) for nine days,
as previously described.23 Brieﬂy, bone marrow was
collected from the tibias of B10.PLxC57BL/6 mice,
and clusters within the bone marrow suspension were
dispersed by vigorous pipetting. Cells were seeded into
six well plates at 2 105/mL in 2mL 10% FCS medium
with the addition of 20 ng/mL of GM–CSF. At day 3,
a further 2mL of medium containing 20 ng/mL of
GM–CSF was added to each well. At day 6, 2mL of
culture supernatant was removed and replaced with
2mL of fresh culture medium containing 20 ng/mL of
GM–CSF. To activate the BMDC, the cells were har-
vested at day 9 and the CD11cþ BMDC were separated
by ﬂuorescence-activated cell sorting (FACS) following
staining with anti-CD11c-FITC (eBioscience, Hatﬁeld,
UK). The cells were re-plated at 2 106 BMDC/mL
with 0.1 mg/mL of LPS (Sigma–Aldrich) and 5 ng/mL
of GM–CSF with 0.1 mg/mL of Ac1-9(4Tyr) for an add-
itional 18 h.
Female B10.PLxC57BL/6 mice received 1 106
Tg4.CD45.1 CD4þ T-cells. One day later, mice
received 2 106 LPS-stimulated, MBP (4Tyr)-pulsed
CD11cþ BMDC at a total volume of 100 mL
injected subcutaneously (50 mL into each hind leg). On
the day of BMDC transfer and 48 h later, each
mouse also received 200 ng of pertussis toxin (Health
Protection Agency) in 0.5mL of PBS intraperitoneally.
Clinical signs of EAE were assessed daily as described
above.
Preparation of mononuclear cells and
FACS analysis
Mice were sacriﬁced by CO2 asphyxiation, perfused
with cold PBS, and mononuclear cells were prepared
from the spleen and CNS as previously described.24
Single cell suspensions made from the spleen underwent
a red blood cell lysis step using an ammonium chloride
buﬀer (Sigma–Aldrich) and the cells were then resus-
pended in FACS buﬀer (PBS, 2% FCS, 0.01% sodium
azide; Sigma Aldrich). Fc receptors were blocked
with supernatant from the hybridoma 2.4G2. The anti-
bodies used were LIVE/DEAD ﬁxable cell stain (Life
Technologies, Carlsbad, CA, USA), anti-CD4-e450
(eBioscience), anti-CD4-AF700 (eBioscience), and
anti-CD45.1-Per-CP (eBioscience). For intracellular
staining in response to peptides, cells were resuspended
at 1 107/mL in the presence or absence of 20 mM of
4Lys MBP. After overnight culture, 1 mL/mL of brefel-
din A (eBioscience) was added for the last 4 h of cul-
ture. Cells were surface-stained prior to processing for
intracellular staining using proprietary buﬀers accord-
ing to the manufacturer’s instruction (for cytokine
staining; BD Biosciences, Franklin Lakes, NJ, USA).
The antibodies used for intracellular cytokine staining
were anti-GM–CSF–PE (eBioscience), anti-IFN–FITC
(eBioscience), anti-IL-17-PerCP (eBioscience), and
anti-TNF-e450 (eBioscience). FACS data were col-
lected using LSR Fortessa (BD Biosciences) and ana-
lysed using FlowJo software (Tree Star, Olten,
Switzerland).
Grading of injection site inflammation
At necropsy, the injection site on the lateral aspect of
the hind leg was examined grossly and scored using the
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previously reported grading system.13 No gross evi-
dence of a subcutaneous swelling scored 0, 1–2mm
swellings scored 1, 2–4mm swellings scored 2, and swel-
lings greater than 4mm scored 3. For histopathological
evaluation, the hind legs were preserved in 4% buﬀered
formaldehyde, decalciﬁed, embedded in paraﬃn, sec-
tioned at 5 mm and stained with haematoxylin and
eosin. The histological appearance of the injection site
was scored based on a previously reported grading
system.13 The reviewer of the slides was blinded to
the experimental group. Sections were taken at
500 mm intervals throughout the hind limb region and
a representative slide was taken from each hind limb for
scoring. No microscopic evidence of inﬂammation
scored 0, mild inﬂammation scored 1, moderate inﬂam-
mation scored 2, and marked to severe inﬂammation
scored 3. The inﬂammation scores of the right and left
legs were averaged for each mouse.
Statistics
The peak EAE scores and inﬂammation scores were
compared using a Mann–Whitney U-test. A t-test was
used to compare the number and proportion of cells
between mice which developed EAE and those which
did not. A power calculation was used to calculate the
number of mice used in the EAE experiment. Mice
immunized with CFA typically had a peak score of
2.7 with a standard deviation of 1.6. If the peak score
in the BMDC group was set at 1.1, the experiment
needed a minimum number of 16 in each group to
have 80% power to detect a diﬀerence between the
two groups at a P value of< 0.05. A Fisher’s exact
test was undertaken to compare the proportion of
mice which developed EAE following immunization
with either CFA or BMDC. Signiﬁcance was set at
P< 0.05.
Results
Literature review of the number of mice
used in EAE experiments
Initially, we estimated the number of mice administered
CFA in EAE experiments by reviewing all studies
which were retrieved in PubMed using the ‘experi-
mental autoimmune encephalomyelitis AND mice’
search term that were published during 2013. This
search retrieved 502 publications, of which 380 studies
reported the use of CFA for inducing EAE.
We reviewed 30 manuscripts in full and found that
the mean number of mice per study immunized with
CFA was 28 (median 23, 25th percentile 8 and 75th
percentile 40). Therefore, approximately 10,640 mice
were reported in scientiﬁc publications to have been
immunized with CFA and autoantigen in EAE experi-
ments in 2013.
MBP-pulsed CD11cþ BMDC or MBP plus
CFA are equally effective at initiating EAE
We investigated our ﬁrst hypothesis by examining
whether our recently described BMDC-driven EAE
model20 was as eﬀective at inducing EAE as CFA
plus MBP immunization was. In our BMDC-driven
EAE model, non-transgenic host mice were ﬁrst
seeded with naı¨ve CD4þ T-cells from Tg4 mice express-
ing a transgenic TCR recognizing the Ac1-9 peptide of
MBP, prior to immunization with MBP-pulsed BMDC.
We have previously shown that immunization with
LPS-matured, MBP-pulsed BMDC was highly eﬀective
at inducing a robust monophasic course of EAE.20 In
the present study, we compared the potentials of MBP-
pulsed CD11cþ BMDC and MBP plus CFA immun-
ization for inducing EAE.20,24 CD11cþ BMDC was
used since CD11cþ expressing cells are highly eﬀective
at activating naı¨ve T-cells.16 We found that both
immunization protocols robustly induced EAE
(Figure 1). There were no signiﬁcant diﬀerences
between the two groups in the proportion of mice
which developed the disease (BMDC 12/16 mice,
CFA 18/21, P¼ 0.44) or in the median peak severity
of disease (BMDC 2.75, CFA 3.0, P¼ 0.69).
Figure 1. Immunization with either complete Freund’s
adjuvant (CFA) plus myelin basic protein (MBP) or CD11cþ
bone marrow-derived dendritic cells (BMDC) is similarly
effective at initiating experimental autoimmune enceph-
alomyelitis (EAE). MBP responsive Tg4 CD4þ T-cells were
transferred into B10.PLxC57BL/6 recipients on day 1.
On day 0, either lipopolysaccharide (LPS)-matured,
MBP-pulsed CD11cþ BMDC or MBP plus CFA were
injected subcutaneously in hind limbs. Pertussis toxin
was administered intraperitoneally at days 0 and 2. The
clinical disease course is shown. The data shown are
pooled from three independent experiments showing
similar results.
4 Laboratory Animals 0(0)
 at The University of Edinburgh on August 3, 2016lan.sagepub.comDownloaded from 
MBP responsive T-cells accumulate in the
CNS of mice which develop EAE following
immunization with MBP-pulsed BMDC
The accumulation of MBP responsive autopathogenic
CD4þ T-cells in the CNS of B10.PLxC57BL/6 mice
which develop EAE following seeding with Tg4 cells
and immunization with CFA plus MBP is well estab-
lished.25 However, it remains unclear whether mice
which develop EAE following immunization with
MBP-loaded BMDC also have an increase in the
number of MBP responsive T-cells within the CNS at
the peak of disease. To examine this issue, we seeded
B10.PLxC57BL/6 hosts with Tg4 CD4þCD45.1þ
T-cells prior to immunization with MBP-loaded
BMDC as per the BMDC-driven EAE protocol. We
sacriﬁced the mice at day 12 and made single cell prep-
aration from the spleen and CNS of all the immunized
mice. For the purposes of the analysis we then split the
mice into two groups based on whether they had devel-
oped EAE or had remained asymptomatic (Figure 2A).
As shown in Figure 2B, there was a signiﬁcant increase
in total CD4þ T-cells and donor CD4þCD45.1þ
Tg4T-cells in the mice which developed disease.
There was also an increase in the proportion of donor
Tg4þ T-cells in the mice which developed EAE.
Furthermore, we found that a signiﬁcant proportion
of the Tg4 CD4þ T-cells were able to produce proin-
ﬂammatory cytokines such as GM–CSF and
IFNg upon re-stimulation with MBP (Figure 2C).
Collectively, these ﬁndings demonstrate that the autop-
athogenic inﬂammatory inﬁltrate in the CNS of mice
which develop EAE post MBP-loaded CD11cþ BMDC
immunization is very similar to the inﬁltrate which has
been previously reported to occur in the CNS of mice
immunized with CFA plus MBP.
MBP plus CFA immunization, but not
CD11cþ BMDC, causes long-standing
injection site inflammation
Following the demonstration that CD11cþ BMDC are
as eﬀective as CFA immunization at inducing disease,
we tested our second hypothesis by investigating the
extent of injection site inﬂammation following immun-
ization with either MBP-loaded CD11cþ BMDC or
CFA plus MBP. We macroscopically and microscopic-
ally examined the injection sites 23 days post immun-
ization in mice immunized with either CFA plus MBP
or CD11cþ BMDC. All mice immunized with CFA
plus MBP had a swelling at the site of injection
(Figure 3A). In contrast, with the CD11cþ BMDC
immunized mice, only one leg had macroscopic
evidence of injection site swelling (Figure 3a)
(P¼ 0.0006). Evidence of mild to moderate
Figure 2. Myelin basic protein (MBP) responsive T-cells
accumulate in the central nervous system (CNS) of mice
which develop experimental autoimmune encephalomyeli-
tis (EAE) following immunization with MBP-pulsed bone
marrow-derived dendritic cells (BMDC). MBP responsive
Tg4 CD45.1þCD4þ T-cells were transferred into
B10.PLxC57BL/6 recipients on day 1. On day 0, MBP-
pulsed CD11cþ BMDC were injected subcutaneously in
hind limbs. Pertussis toxin was administered intraperito-
neally at days 0 and 2 post CD11cþ BMDC transfer. Mice
were sacrificed at day 12 and for analysis purposes they
were split into mice which developed disease (n¼ 5) and
those which did not (n¼ 6). (a) Disease course is shown.
(b) Spleen and CNS were harvested for flow cytometry
analysis of total CD4þ and donor CD4þCD45.1þ Tg4 cells.
The total numbers of cells, number of donor CD4þCD45.1þ
Tg4 cells, and percentage of donor CD4þCD45.1þ Tg4 cells
of total CD4þ cells are shown. (c) The percentages of
CD4þCD45.1þ Tg4 cells recovered from the CNS which
were positive for intracellular cytokine staining following
overnight stimulation with MBP are shown. Data are from
one of two independent experiments containing the same
number of mice giving consistent results.
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inﬂammation was routinely observed in mice immu-
nized with CFA plus MBP, whereas only occasional
mice had evidence of mild inﬂammation at the
CD11cþ BMDC injection site (Figures 3A and B)
(P¼ 0.0006). The inﬂammatory inﬁltrate in the CFA-
injected mice contained a mixture of cells including
macrophages, neutrophils and lymphocytes located in
the subcutis and underlying musculature.
Discussion
EAE models involving the administration of CFA and
a CNS autoantigen have been instrumental in advan-
cing understanding of the pathophysiology of auto-
immune disorders and in the development of novel
therapies. Their success has resulted in the development
of a wide range of CFA and autoantigen-driven auto-
immune models involving other body systems. These
include CFA and autoantigen-driven autoimmune
myocarditis,26 arthritis,27 thyroiditis,28 uveitis29 and
orchitis30 models. Establishing the precise numbers of
mice used each year in CFA-induced models of auto-
immunity is diﬃcult. Our study has estimated that over
10,000 mice had been immunized with CFA in EAE
experiments which had been published in scientiﬁc
papers during a single year. It is highly likely that
many more mice were used in CFA-induced EAE
experiments which were not reported in a published
manuscript. Furthermore, large numbers of mice are
immunized with CFA in non-EAE autoimmunity
experiments. Therefore, our ﬁnding that several thou-
sand mice each year are immunized with CFA to study
the development of autoimmunity in vivo is likely to be
a gross under-estimation of the total number.
Our study found that immunization with CFA was
associated with marked localized inﬂammation at the
site of injection. This is consistent with previous studies
that have demonstrated signiﬁcant pathological
changes following subcutaneous injection of CFA.11
For example, the subcutaneous injection of CFA in
mice has been shown to result in marked to severe
granuloma formation, diﬀuse exudative inﬂammation
and ﬁbrosis.13,31 Following the subcutaneous adminis-
tration of CFA, mice showed reduced movement
and impaired vertical activity.14 In addition, mice
immunized with CFA showed decreased running time
on forced treadmill tests.14 Collectively, these behav-
ioural changes lead to the conclusion that CFA immun-
ization results in behavioural responses suggestive of
pain.14
Figure 3. Immunization with complete Freund’s adjuvant (CFA) plus myelin basic protein (MBP), but not bone marrow-
derived dendritic cells (BMDC), causes injection site inflammation. Mice were immunized with either CFA plus MBP (n¼ 7)
or MBP-loaded BMDC (n¼ 7) as part of the standard experimental autoimmune encephalomyelitis (EAE) induction
protocol described in Figure 1. Twenty-five days post immunization, the injection sites were macroscopically examined for
evidence of swelling. The injection sites were also examined microscopically for evidence of inflammation. (a) Injection
site lesions were scored as detailed in Materials and methods. The histogram shows the mean value and standard error
mean. (b) Representative histological examples of hind limbs from mice injected with MBP-loaded BMDC (BMDC) or CFA
plus MBP (CFA) (haematoxylin and eosin stain). There is a mixed inflammatory infiltrate particularly in the subcutis and
muscle of CFA plus MBP-injected mice. There is also evidence of myositis and myofiber degeneration in the CFA plus
MBP-injected mice. Data are representative of two independent experiments containing the same number of mice, giving
consistent results. The scale bar represents 500 mm.
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Since several thousand mice per year are immunized
with CFA, which causes signiﬁcant inﬂammation and
behavioural responses suggestive of pain, there is a
need to develop models which allow the in vivo devel-
opment of autoimmunity to be studied without the
injection site side-eﬀects associated with CFA immun-
ization. Previous studies have attempted to address this
problem by immunizing mice with autoantigen-loaded
DC rather than by immunizing with CFA and CNS
autoantigen. However, none of the previously reported
DC-driven EAE models have been widely employed
due to a range of issues including the requirement for
repeated injections of BMDC to induce EAE or the
need for concurrent administration of CFA to drive
robust disease.17,19 A previous report of MBP-pulsed
DC-driven EAE diﬀered markedly from ours in that
10 times as many MBP-reactive T-cells were transferred
and the host mice were irradiated prior to cell trans-
fer.18 Therefore, our study is the ﬁrst demonstration, to
the authors’ knowledge, of a robust BMDC-driven
EAE model which can initiate clinical autoimmune
pathology as eﬀectively as CFA and CNS autoantigen
immunization. We have also demonstrated that in
mice which develop EAE following the transfer
of MBP-loaded BMDC there is an accumulation of
MBP responsive T-cells which are capable of
producing proinﬂammatory cytokines. Furthermore,
we demonstrated that, in contrast to CFA immuniza-
tion, BMDC immunization causes no long-term injec-
tion site inﬂammation. It is likely that the
subcutaneously administered BMDC rapidly migrate
to the draining lymph nodes where they subsequently
prime the naı¨ve Tg4 CD4þ T-cells without causing any
signiﬁcant subcutaneous inﬂammation.
A potential limitation of the BMDC-driven EAE
model described in this paper is the requirement to
use B10.PLxC57BL/6 hosts rather than the C57BL/6
hosts which are frequently used in EAE experiments.
Immunization of C57BL/6 mice with myelin oligo-
dendrocyte glycoprotein (MOG) is one of the most
commonly used approaches for inducing EAE due to
the wide availability of genetically-modiﬁed mice with a
C57BL/6 background. Another potential limitation is
the absence of a control group of PBS-injected mice.
This was because our initial preliminary experiments
demonstrated that there was very little inﬂammation
at the injection site following administration of
CD11cþ BMDC. Consequently, we felt it was ethically
unjustiﬁable to use additional mice for a PBS injection
control group when our key aim was to compare the
eﬃcacy and side-eﬀects of CFA and BMDC injections.
Despite these limitations, our model represents a sig-
niﬁcant experimental reﬁnement which has the capacity
to improve the welfare of large numbers of experimen-
tal animals.
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